Three Munich Re Board Members Buy Shares at Lows as a Technical Pattern Hints at Recovery

Munich Re posts 57% profit jump, board buys shares, and a bullish chart pattern emerges, but pricing pressure and weak dollar keep stock near 52-week low. Analysts split.

The disconnect between Munich Re’s operating strength and its stock price has rarely been wider. The reinsurer posted a 57% jump in first-quarter net profit, its board has stepped in with coordinated insider purchases, and a fresh chart signal emerged on Friday. Yet the shares remain near a 52-week low, weighed down by pricing pressure in the renewal market and a weak dollar.

Net profit for the first three months of 2026 came in at roughly €1.7 billion, up sharply from the prior-year period. The main driver was a benign natural catastrophe season: large claims in property and casualty reinsurance totalled just €130 million, compared with more than €1 billion in early 2025 when California wildfires ravaged the portfolio. Investors nevertheless marked the stock down about 5% on earnings day, reflecting concerns that the strong underwriting result may prove temporary.

That unease has not deterred the top brass. On 12 May, three management board members — Dr. Achim Kassow, Stefan Golling and Dr. Markus Rieß — bought shares through XETRA. Kassow paid €470.00 for 300 shares, Golling acquired stock at an average price of €476.19, and Rieß picked up 500 shares at €476.50 each. Such a multi-executive buying spree is unusual and is typically read by the market as a belief that the recent sell-off has overshot.

The technical backdrop adds another layer of intrigue. The stock closed Friday at €475.10, gaining 1.41%, and an “expansion breakdown” signal appeared on 13 May. In the current context, that pattern is considered a long indicator. The move came after a sharp 30-day decline of 15.61%, which has left the shares down 13.46% year to date. The relative strength index sits at 72.2, signalling short-term overbought conditions even as the broader trend remains weak — a configuration that often leaves technical traders on edge.

The analyst community is split. DZ Bank maintains a positive stance, while Goldman Sachs is neutral. RBC, Berenberg and Jefferies have adopted a more cautious tone. Much will depend on whether the stock can stay clear of the nearest support at €467.30. A push back towards that level would quickly undermine the nascent recovery.

The market’s wariness has concrete causes. During the 1 April renewal round, Munich Re’s new business shrank by 18.5%, and after adjusting for inflation and risk shifts, prices fell 3.1%. Rival Hannover Re expanded its portfolio in the same period despite a similar pricing environment, highlighting competitive pressure. Currency headwinds are also biting: many reinsurance contracts are denominated in dollars, and a weaker greenback reduced insurance contract revenue by nearly €800 million, bringing the total to €15 billion. Claims related to the Persian Gulf conflict have reached roughly €90 million so far — manageable, but an additional uncertainty.

Against this backdrop, the company has launched the first tranche of its institutional buyback programme. Starting on 14 May, Munich Re plans to repurchase shares worth up to €900 million, representing about 1.5% of its share capital, by 21 August 2026. The entire programme has a total volume of up to €2.25 billion and runs until the annual general meeting in April 2027.

Management is sticking to its full-year guidance: group insurance revenue of around €64 billion and net profit of roughly €6.3 billion. The true test will come in the July renewal season. CFO Buchanan has said he expects pricing levels to be “broadly maintained” — a statement that, if borne out, would remove the most potent argument against the stock.

For the expansion breakdown signal to gain real weight, the stock needs follow-through buying in the sessions ahead. The Friday bounce, combined with insider purchases and the forthcoming buyback, gives the bulls some ammunition. But until the market sees evidence that the renewal cycle is stabilising, the scepticism looks unlikely to fade.